Biosensors   

Is Biosensors a good buy?

Compare Leader's Trial for Biomatrix

 

The two stents performed equivalently across all three tertiles. At two years follow-up there

was a non-significant trend towards a lower rate of major adverse cardiac events (MACE) in

patients treated with the BioMatrix Flex stent compared with those treated with the Cypher

Select stent in the SXhigh tertile (15.3% vs. 21.8%: p=0.08). The cardiac death rate was

significantly lower in the SXhigh patients treated with the BioMatrix Flex stent compared

with those treated with the Cypher Select stent (4.7% vs. 9.6%: p=0.045).

 

1.30 still hold very well. Volume for the last few days have been decreasing significantly while the price  stabilizing. No sign of turning down yet. Most likely will be side way for a way before deciding which direction to go. My personal take is, it will most likely to continue its prior trend, going up.

infancybird      ( Date: 21-Apr-2011 08:01) Posted: abkxpress, let us know your short result ...either get shot by the market or  you get your roast duck /suckling pig. Many shortist only declare their meals but never admit being shot. We be eagerly awaiting your result please.  Please go ahead to short as you declare.      abkxpres      ( Date: 20-Apr-2011 15:51) Posted: The last 3 weeks had been wonderful for biosensors with an exceptionally good run.   Many people had a good run.   I make some money from 1.18-1.27 and I seen super bullish in this counter because when other counters even global ones are down, Biosensors is still gaining or holding.   However, the wind have changed and it had reached its first interval.   Today everybody is up except Biosensors.   This is a sign of breathlessness especially with all its indicators peaking.   In fact its RSI is turning to the down side.   I've made more money shorting this counter the last time and now is the BEST TIME.   It's definitely going down, I shorted at 1.33 and 1.32 so everybody don't miss this chance.   It should at least be 1.29 or lower by Friday.   SHORT SHORT SHORT!!!

 

MACE

Biosensors end of 3rd year 15.7%

XIENCE end of 2nd Year 7.3%

 

Though Biomatrix results is 3year versus XIENCE 2 year, XIENCE seems to provide better outcome.

 

 

NEW ORLEANS, April 3, 2011 /PRNewswire via COMTEX/ -- A pooled analysis of the SPIRIT II, III, IV and COMPARE trials presented today further reinforces the positive clinical performance of Abbott's /quotes/comstock/13*!abt/quotes/nls/abt ABT -0.20% market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System. As part of the analysis of all four trials, two-year results on the safety and efficacy of XIENCE V compared to TAXUS(R) Liberte(R) and TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent Systems (TAXUS) were presented at the American College of Cardiology's (ACC) 60th Annual Scientific Session and i2 Summit 2011 in New Orleans.

In a presentation given by Dean J. Kereiakes, M.D., medical director of The Christ Hospital Heart and Vascular Center in Cincinnati, Ohio, predictors of artery re-blockage, cardiac death or heart attack were evaluated out to two years in nearly 7,000 patients from the SPIRIT II, III, IV and COMPARE clinical trials. The data demonstrated that use of XIENCE V resulted in significantly lower clinical event rates following a stent procedure. In the pooled analysis, XIENCE V demonstrated a 36 percent reduction in the risk of major adverse cardiac events (MACE) compared to TAXUS (7.3 percent for XIENCE V versus 11.1 percent for TAXUS, p-value< 0.001). MACE is an important composite clinical measure of safety and efficacy outcomes for patients, defined as cardiac death, heart attack (myocardial infarction or MI), or retreatment of a lesion (ischemia-driven target lesion revascularization, or ID-TLR).

" XIENCE V consistently demonstrated low adverse cardiac event rates in trial after trial," said Dr. Kereiakes. " The SPIRIT II, III, IV, and COMPARE pooled analysis suggests that XIENCE V reduced the occurrence of adverse events compared to patients treated with the TAXUS stent. The low event rates demonstrated by XIENCE V in these trials are especially impressive given the complexity of patients in the SPIRIT IV and COMPARE trials and confirm that the results seen with XIENCE V in earlier randomized clinical trials are consistent with clinical practice."

XIENCE V Shows Positive Results in Data Presented at ACC

In addition to the 36 percent reduction in the risk of overall MACE compared to TAXUS, data also were presented at ACC from the pooled analysis that demonstrated the following for XIENCE V:

A 47 percent reduction in the risk of heart attack (2.9 percent for XIENCE V versus 5.5 percent for TAXUS, p-value< 0.001)

A 40 percent reduction in the risk of cardiac death or heart attack (4.0 percent for XIENCE V versus 6.6 percent for TAXUS, p-value< 0.001)

A 36 percent reduction in the risk of ID-TLR (4.1 percent for XIENCE versus 6.6 percent for TAXUS, p-value< 0.001)

A 70 percent reduction in the risk of stent thrombosis, defined as definite or probable according to ARC (Academic Research Consortium) (0.7 percent for XIENCE V vs. 2.3 percent for TAXUS, p-value< 0.0001)

" The pooled analysis of the SPIRIT II, III, IV and COMPARE trials further supports the strong body of clinical evidence that has made XIENCE V a leading drug eluting stent technology for patients and physicians," said Charles A. Simonton, M.D., FACC, FSCAI, divisional vice president, Medical Affairs, and chief medical officer, Abbott Vascular. " XIENCE V's long-term clinical performance is backed by clinical data from more than 30,000 patients worldwide."

The SPIRIT trials were sponsored and conducted by Abbott. SPIRIT IV included 3,690 patients, many of whom presented with multiple medical complexities, including more than 1,100 patients with diabetes, and patients with small vessels, long lesions, and multiple lesions. The COMPARE study was a physician-initiated trial involving 1,800 patients with complex vascular disease. This pooled analysis was performed independently of Abbott. TAXUS Liberte was the control in COMPARE and TAXUS Express2 was the control in SPIRIT II, SPIRIT III and SPIRIT IV.

 

abkxpress,

let us know your short result ...either get shot by the market or  you get your roast duck /suckling pig. Many shortist only declare their meals but never admit being shot. We be eagerly awaiting your result please.  Please go ahead to short as you declare.     

abkxpres      ( Date: 20-Apr-2011 15:51) Posted: The last 3 weeks had been wonderful for biosensors with an exceptionally good run.   Many people had a good run.   I make some money from 1.18-1.27 and I seen super bullish in this counter because when other counters even global ones are down, Biosensors is still gaining or holding.   However, the wind have changed and it had reached its first interval.   Today everybody is up except Biosensors.   This is a sign of breathlessness especially with all its indicators peaking.   In fact its RSI is turning to the down side.   I've made more money shorting this counter the last time and now is the BEST TIME.   It's definitely going down, I shorted at 1.33 and 1.32 so everybody don't miss this chance.   It should at least be 1.29 or lower by Friday.   SHORT SHORT SHORT!!!! stanley888      ( Date: 20-Apr-2011 09:34) Posted: IMHO, Biosensors is an strong uptrending stock. I will not choose to short it as the risk is high because we are going  against the trend. The are other better (weaker) stocks to short, such as Yanlord, CapmallsAsia, FalconEne etc.. http://pick-the-winning-stock.blogspot.com/2011/04/sgp-stocks-weekly-update-4182011.html

 

with dow up by 180 points.st index will follow with 1% up.

shortiing  will be  out of money,

they have cover by friday  ,so expect buying at 1.37-1.45 if stock move up 1% within 2 days

 

Good luck!! Just beware that volume for the last few days (today included) has been quite low when it take a breath.. which may suggest temporary rest. 1.30 must break for it to go down further. just my 2 cents.

abkxpres      ( Date: 20-Apr-2011 15:51) Posted: The last 3 weeks had been wonderful for biosensors with an exceptionally good run.   Many people had a good run.   I make some money from 1.18-1.27 and I seen super bullish in this counter because when other counters even global ones are down, Biosensors is still gaining or holding.   However, the wind have changed and it had reached its first interval.   Today everybody is up except Biosensors.   This is a sign of breathlessness especially with all its indicators peaking.   In fact its RSI is turning to the down side.   I've made more money shorting this counter the last time and now is the BEST TIME.   It's definitely going down, I shorted at 1.33 and 1.32 so everybody don't miss this chance.   It should at least be 1.29 or lower by Friday.   SHORT SHORT SHORT!!!! stanley888      ( Date: 20-Apr-2011 09:34) Posted: IMHO, Biosensors is an strong uptrending stock. I will not choose to short it as the risk is high because we are going  against the trend. The are other better (weaker) stocks to short, such as Yanlord, CapmallsAsia, FalconEne etc.. http://pick-the-winning-stock.blogspot.com/2011/04/sgp-stocks-weekly-update-4182011.html

 

The last 3 weeks had been wonderful for biosensors with an exceptionally good run.   Many people had a good run.   I make some money from 1.18-1.27 and I seen super bullish in this counter because when other counters even global ones are down, Biosensors is still gaining or holding.   However, the wind have changed and it had reached its first interval.   Today everybody is up except Biosensors.   This is a sign of breathlessness especially with all its indicators peaking.   In fact its RSI is turning to the down side.   I've made more money shorting this counter the last time and now is the BEST TIME.   It's definitely going down, I shorted at 1.33 and 1.32 so everybody don't miss this chance.   It should at least be 1.29 or lower by Friday.   SHORT SHORT SHORT!!!!

stanley888      ( Date: 20-Apr-2011 09:34) Posted: IMHO, Biosensors is an strong uptrending stock. I will not choose to short it as the risk is high because we are going  against the trend. The are other better (weaker) stocks to short, such as Yanlord, CapmallsAsia, FalconEne etc.. http://pick-the-winning-stock.blogspot.com/2011/04/sgp-stocks-weekly-update-4182011.html  swissvic      ( Date: 20-Apr-2011 08:38) Posted: only 2000 share was sold at 1.33 yesterday ,so you short most of lots at 1.32. so if today with dow up back by 50% of loss..,singapore will also recover. so be careful ,so it will move to 1.33 today or  higher..

 

IMHO, Biosensors is an strong uptrending stock. I will not choose to short it as the risk is high because we are going  against the trend. The are other better (weaker) stocks to short, such as Yanlord, CapmallsAsia, FalconEne etc..

http://pick-the-winning-stock.blogspot.com/2011/04/sgp-stocks-weekly-update-4182011.html 

swissvic      ( Date: 20-Apr-2011 08:38) Posted: only 2000 share was sold at 1.33 yesterday ,so you short most of lots at 1.32. so if today with dow up back by 50% of loss..,singapore will also recover. so be careful ,so it will move to 1.33 today or  higher..

 

only 2000 share was sold at 1.33 yesterday ,so you short most of lots at 1.32.

so if today with dow up back by 50% of loss..,singapore will also recover.

so be careful ,so it will move to 1.33 today or  higher..

 

OkieDokie,   I have just shorted 300 lots at 1.33 and 1.32.   The last time I told everyone OCBC is dumping whilst I was longing it at 1.14 then I reveresed and start to short it.   Nobody believe me and I had people like you as sitting ducks letting me short until below 1.00   I've made a nice pile about 300 lots with average of 0.13 profits.

 

Again, this is showing the sign of a good shorting opportunity.   I will short further when it hits 1.29 again and I need people like to buy so I can have roast ducks again.

 

Many dun believe that what goes up must come down sometime and vice versa.   People who hold for the long term are not making the opportunity profits when things turn.   This is a great turning point and all the TA are showing peaks at the long now.   It must go down before coming up.   I should at least make 4-5 cents each lots then I will long this good counter when it drops to it lower support maybe 1.25/1.21/1.19 etc depending on the TA conditions.   If all hell break lose, it may drop below 1.18 which is a great support or even 1.11 which is an even stronger support.

 

OkieDokie      ( Date: 19-Apr-2011 09:40) Posted: abkexpres, Go ahead SHORT IT ! Am standing by to  BUY when it is lower or    SELL when others are covering their positions subsequently. Happening counter where opportunities prevail both ways ! abkxpres      ( Date: 19-Apr-2011 00:02) Posted: This counter is bullish and is on the uptrend now but all indicators are peaking and there is no more room to rise in this current gear.   It should drop quite obviously to maybe 1.19 or below before it will shift into its 2nd gear to break 1.35.   My advise is " Short this counter" .......I've been successful in shorting this counter and I'm telling you that this is the best level now at 1.34 to short.   It should drop to at least 1.26/27 without much problem and may drop further to 1.19 if condition allows.   Then long it if below 1.19

 

Biosensors is at critical 1.31 level. Trading below 1.31 will confirm yesterday's hanging man and reversal may happen. But this is a strong uptrending stock. So the short term reversal may be a normal thing to have before it continues its run up. it also provide opportunities to those who miss the previous run. Let's watch and see.

stanley888      ( Date: 19-Apr-2011 06:45) Posted: Biosensors is very toppish now with hanging man formed yesterday. potential short term reversal may happen. today's price action will have to confirm if in deed it will reverse. Do watch out closely if you are holding onto this stock. http://pick-the-winning-stock.blogspot.com

 

abkexpres,

Go ahead SHORT IT ! Am standing by to  BUY when it is lower or    SELL when others are covering their positions subsequently. Happening counter where opportunities prevail both ways !

abkxpres      ( Date: 19-Apr-2011 00:02) Posted: This counter is bullish and is on the uptrend now but all indicators are peaking and there is no more room to rise in this current gear.   It should drop quite obviously to maybe 1.19 or below before it will shift into its 2nd gear to break 1.35.   My advise is " Short this counter" .......I've been successful in shorting this counter and I'm telling you that this is the best level now at 1.34 to short.   It should drop to at least 1.26/27 without much problem and may drop further to 1.19 if condition allows.   Then long it if below 1.19. investor      ( Date: 16-Apr-2011 15:38) Posted: What does the mkt expect Biosensors to earn for yr ending mar 2011 ? To answer this question, look at what the analysts are saying. DBS forecast net profit of  US$37m, OCBC forecast US$39.8m, and Nomura forecast US$40.5m. All of them quite close. These figures above include exceptional losses of US$10.915m due to one-time write-offs and warrant derivative depn, ie without them Biosensors will earn more. As at 9 mths, results show a net profit of US$25.043m. THat is to meet the analyst's expectation, Biosensors need to earn US$12m, based on DBS forecast, US$14.8m based on OCBC's forecast, and US$15.5m based on Nomura's forecast. If we look at Q3 2011 results, Biosensors earned US$13.3m, so it looks likely that the coming Q4 results will not be far off from here. Also, comments from mgmt shows that although they expect DES   growth from Europe to slow down (from a high of 26 % growth qtr on qtr), they expect growth from Asia to be stronger, going forward. All in all, I don't see the coming results to be very different, and in fact, a flat qtr on qtr growth would be sufficient for me, ie if they earned another US13.3m in Qtr 4, it is good enough. If you scrutinise the latest Nomura's report dated 8th Apr 2011,  the main theme is about the GROWING IMPORTANCE of China, India, Indonesia, in the coming years, and Biosensors seems to have a head start in at least one of this mkt, ie China, and I believe they are also doing quite a bit in India (there is a clinical trial registry). That is probably one of the main reasons for the rise in share price, other than the approval in Japan, and possibly China in the near term. Having said all these, the rise in share price looks quite steep, and overbought, and it is anybody's guess where it will go from here, although it remains true that the strong uptrend is still intact, even if you get a correction now and then. Technically, I will only get concerned, if the price close below 1.09 or below 1.05 (near 200 day mva) or worse below 0.96. Again, not a call to buy/sell.

 

this stock is not for short at this stage as  there  is   support ,just before closing there was a buy of 500,000 over share

at 1.34 .chinese are support this counter. so be careful.they have deep pocket these chinese funds

 

Biosensors is very toppish now with hanging man formed yesterday. potential short term reversal may happen. today's price action will have to confirm if in deed it will reverse. Do watch out closely if you are holding onto this stock.

http://pick-the-winning-stock.blogspot.com 

 

pls short it down so i can buy it cheap. thanks

 

This counter is bullish and is on the uptrend now but all indicators are peaking and there is no more room to rise in this current gear.   It should drop quite obviously to maybe 1.19 or below before it will shift into its 2nd gear to break 1.35.   My advise is " Short this counter" .......I've been successful in shorting this counter and I'm telling you that this is the best level now at 1.34 to short.   It should drop to at least 1.26/27 without much problem and may drop further to 1.19 if condition allows.   Then long it if below 1.19.

investor      ( Date: 16-Apr-2011 15:38) Posted: What does the mkt expect Biosensors to earn for yr ending mar 2011 ? To answer this question, look at what the analysts are saying. DBS forecast net profit of  US$37m, OCBC forecast US$39.8m, and Nomura forecast US$40.5m. All of them quite close. These figures above include exceptional losses of US$10.915m due to one-time write-offs and warrant derivative depn, ie without them Biosensors will earn more. As at 9 mths, results show a net profit of US$25.043m. THat is to meet the analyst's expectation, Biosensors need to earn US$12m, based on DBS forecast, US$14.8m based on OCBC's forecast, and US$15.5m based on Nomura's forecast. If we look at Q3 2011 results, Biosensors earned US$13.3m, so it looks likely that the coming Q4 results will not be far off from here. Also, comments from mgmt shows that although they expect DES   growth from Europe to slow down (from a high of 26 % growth qtr on qtr), they expect growth from Asia to be stronger, going forward. All in all, I don't see the coming results to be very different, and in fact, a flat qtr on qtr growth would be sufficient for me, ie if they earned another US13.3m in Qtr 4, it is good enough. If you scrutinise the latest Nomura's report dated 8th Apr 2011,  the main theme is about the GROWING IMPORTANCE of China, India, Indonesia, in the coming years, and Biosensors seems to have a head start in at least one of this mkt, ie China, and I believe they are also doing quite a bit in India (there is a clinical trial registry). That is probably one of the main reasons for the rise in share price, other than the approval in Japan, and possibly China in the near term. Having said all these, the rise in share price looks quite steep, and overbought, and it is anybody's guess where it will go from here, although it remains true that the strong uptrend is still intact, even if you get a correction now and then. Technically, I will only get concerned, if the price close below 1.09 or below 1.05 (near 200 day mva) or worse below 0.96. Again, not a call to buy/sell.

 

What does the mkt expect Biosensors to earn for yr ending mar 2011 ?

To answer this question, look at what the analysts are saying. DBS forecast net profit of  US$37m, OCBC forecast US$39.8m, and Nomura forecast US$40.5m.

All of them quite close. These figures above include exceptional losses of US$10.915m due to one-time write-offs and warrant derivative depn, ie without them Biosensors will earn more.

As at 9 mths, results show a net profit of US$25.043m. THat is to meet the analyst's expectation, Biosensors need to earn US$12m, based on DBS forecast, US$14.8m based on OCBC's forecast, and US$15.5m based on Nomura's forecast.

If we look at Q3 2011 results, Biosensors earned US$13.3m, so it looks likely that the coming Q4 results will not be far off from here.

Also, comments from mgmt shows that although they expect DES   growth from Europe to slow down (from a high of 26 % growth qtr on qtr), they expect growth from Asia to be stronger, going forward.

All in all, I don't see the coming results to be very different, and in fact, a flat qtr on qtr growth would be sufficient for me, ie if they earned another US13.3m in Qtr 4, it is good enough.

If you scrutinise the latest Nomura's report dated 8th Apr 2011,  the main theme is about the GROWING IMPORTANCE of China, India, Indonesia, in the coming years, and Biosensors seems to have a head start in at least one of this mkt, ie China, and I believe they are also doing quite a bit in India (there is a clinical trial registry).

That is probably one of the main reasons for the rise in share price, other than the approval in Japan, and possibly China in the near term.

Having said all these, the rise in share price looks quite steep, and overbought, and it is anybody's guess where it will go from here, although it remains true that the strong uptrend is still intact, even if you get a correction now and then.

Technically, I will only get concerned, if the price close below 1.09 or below 1.05 (near 200 day mva) or worse below 0.96.

Again, not a call to buy/sell.

 

can still take the chance if retrace back to 1.25-1.26. Remember to calculate your risk reward ratio

rogeryap      ( Date: 16-Apr-2011 13:23) Posted: Sounds scary